Sunitinib versus interferon alfa in metastatic renal-cell carcinoma - sprookjes - yvandenbroek - TriplyDB

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

http://www.wikidata.org/entity/Q28282757

about

Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies Targeted therapy for advanced renal cell carcinoma SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression A comprehensive overview of targeted therapy in metastatic renal cell carcinoma mTOR inhibitors in advanced renal cell carcinoma Axitinib for the management of metastatic renal cell carcinoma Accurate molecular classification of renal tumors using microRNA expression State of the science: an update on renal cell carcinoma Histological reclassification, histochemical characterization and c-kit immunoexpression in renal cell carcinoma Immunobiology and immunotherapy in genitourinary malignancies Contemporary Treatment of Metastatic Renal Cell Carcinoma Review of renal cell carcinoma and its common subtypes in radiology Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma Thyroid Hormones as Renal Cell Cancer Regulators Recent developments in receptor tyrosine kinases targeted anticancer therapy Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives Heritable Cancer Syndromes Related to the Hypoxia Pathway Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma Cytoreductive surgery in the era of targeted molecular therapy Profile of nintedanib in the treatment of solid tumors: the evidence to date Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy Withdrawal of anticancer therapy in advanced disease: a systematic literature review Molecular and immunologic markers of kidney cancer-potential applications in predictive, preventive and personalized medicine The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma Therapeutic challenges in renal cell carcinoma Contemporary approaches for imaging skeletal metastasis Renal cell carcinoma: histological classification and correlation with imaging findings Combining radiotherapy with sunitinib: lessons (to be) learned Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials

P2860

Q21203678-BCD84B66-CA91-4DFD-9456-DD699C7C4832 Q21260390-CA77B26D-0D20-41D3-9920-0C83B9327E00 Q21261307-6D23FA05-3FF6-4C70-AF85-25A54C90B5E9 Q24242946-85FFFE1C-E6E7-4C74-9400-9BE991F412B7 Q24339492-914C2470-E1D9-40EB-8AB8-C99FEA696855 Q24595357-E3789B0C-7BEC-4E6B-A31E-D4B51C5A73AA Q24606852-F2BE4517-B3E2-44FD-8063-3F69C3188FAD Q24612127-2671FC38-5F78-4692-9E58-C29D313A9219 Q24613720-E52D4FB1-88B4-407D-8F7C-A153C49ADDDB Q24625843-62CB4304-1427-408D-8C15-0A7F99F16B6E Q24630685-B818FF46-9AEB-4AEB-A17C-4CB29ADD324D Q24658263-010EA870-06AA-47CD-9DE7-5F6FD6482A56 Q26738668-76EDC4FB-F1CB-4CAE-AAAB-1DA025FAD54B Q26740594-BB61F503-0FB4-4FC4-B569-A8CE510F0C11 Q26744297-5AD20FC8-767D-43A5-A7F9-B8C26653D368 Q26747767-B4ED2CF7-AEB6-419C-8449-C40C5595EC43 Q26748991-926D2443-E0FD-4C0B-8FD6-330986BEE067 Q26751331-B198DC90-4C93-460C-ADAE-3DEA3A52B7F6 Q26751341-F2739566-AB4F-4BCA-A3A2-18CD1A5E12CA Q26751590-C85FC7B8-28FF-4B81-841F-418BBE5EFEDB Q26766240-B5A27547-9E28-465B-AE29-79A4C6BFC6E1 Q26772206-051A7F1F-3229-4F23-AE36-42C02F72E58A Q26773653-34B99C7C-0934-4C92-AFFD-31AEFBBD0E5A Q26774134-934C526C-71D4-47A7-9B11-4F716FC3E4B6 Q26775134-2841167F-7856-4BCD-8975-B07DE51D9B5A Q26775769-53295648-090A-4B33-BF37-9C03879893BA Q26777144-B15CF275-8A17-4D14-B062-0D152E4735E2 Q26777486-E5BEDA1E-CF15-4C2B-A0E3-8CB05C0BDCA9 Q26779144-97C319B2-E579-429C-AA4C-B4D13A446FE0 Q26779248-68CA0149-9A5F-4732-A1FD-5C3C4E320686 Q26781662-C78D6642-4FB9-41D2-9CE3-C61C8C4A8004 Q26783520-73D14439-99FC-4037-8215-78B55CAA95B4 Q26786243-F9BBC34B-ABDA-465B-A9D4-B5DB9DE770A7 Q26786534-FE0DF49A-7ADF-49D9-9415-3F9E6C3274F8 Q26796702-96197FDF-E447-41ED-ABA4-D1AF8C5E479B Q26798170-FA35A132-C481-44BF-9168-B9B87A7194C8 Q26799781-174B91CB-B2BD-467D-A965-3EDB04F7017B Q26800587-F9C86BDD-4EAA-4449-8340-2B3F7069A61B Q26801279-6EB8EBCC-77E9-4389-AD0A-7ECC509579C8 Q26822790-47C71AFE-6722-4E00-AFFE-1EB8894F590D

P2860

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

http://www.wikidata.org/entity/Q28282757

description

2007 nî lūn-bûn

@nan

2007 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@ast

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@en

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@nl

type

label

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@ast

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@en

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@nl

prefLabel

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@ast

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@en

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@nl

P1433

Q28282757-6BFFCB00-E167-4B56-B0A3-8D330DCC9BAF

P1476

Q28282757-DDF9E607-DCEC-43C6-B5B1-7D449F3B04AF

P2093

Q28282757-2D747213-1F29-4BAE-8F5C-F7A3A13C910F

Q28282757-42DD61EE-1F68-418A-A690-A4A9C450D488

Q28282757-58D8CD2C-668C-49F5-813A-D883C67610DE

Q28282757-593661A8-6E1A-41FE-84BD-53406064D76A

Q28282757-67BE2F88-791C-4F9F-9BA0-1C23EEA268CD

Q28282757-7554CAE9-9ED0-4E6D-AFDA-1207C7910747

Q28282757-7AE48896-7AD1-4A44-8DD2-F02AEF79BB79

Q28282757-8CB80395-8102-455C-9A38-99AB9D35A532

Q28282757-C87A646E-7773-4959-8BBB-3E34D5E118C0

Q28282757-C967DA66-F95F-4BC4-8490-70FDAC531D81

P304

Q28282757-C599D03D-359F-47B2-9C6A-0769643846AF

P31

Q28282757-BCBAA06C-B6C6-4648-B76E-BDB055E601FB

P3181

Q28282757-02398775-CD9F-4FA5-8A26-B27CDB605AD2

P356

Q28282757-4D305CB4-799D-4DAB-BD25-2C2FE5C0E6D4

P407

Q28282757-FA09E249-0E30-412D-A7DA-CA9E38A8B604

P433

Q28282757-93853609-CA13-43B3-8771-5D28FCC1ABEA

P478

Q28282757-E1FFDB09-9ACC-4F43-9799-A715ACA4DBDC

P50

Q28282757-237928D3-4C67-459E-ABD9-E0C82FF92CF3

Q28282757-44EEAAFE-8A40-4CB2-BBBC-68B956D52BBA

P577

Q28282757-FC4B7C32-1FE5-4210-90C6-F98E135B9E24

P5875

Q28282757-1B71F359-CDE3-4AEC-AC71-2A7AE6E7CD99

P698

Q28282757-9EE7D9A1-B251-4D40-9EDD-D3105206DDA3

P3181

P356

P1433

The New England Journal of Medicine

P1476

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

@en

P2093

Cezary Szczylik

http://www.w3.org/2001/XMLSchema#string

Charles M Baum

http://www.w3.org/2001/XMLSchema#string

Isan Chen

http://www.w3.org/2001/XMLSchema#string

M Dror Michaelson

http://www.w3.org/2001/XMLSchema#string

Paul W Bycott

http://www.w3.org/2001/XMLSchema#string

Piotr Tomczak

http://www.w3.org/2001/XMLSchema#string

Robert A Figlin

http://www.w3.org/2001/XMLSchema#string

Ronald M Bukowski

http://www.w3.org/2001/XMLSchema#string

Sindy T Kim

http://www.w3.org/2001/XMLSchema#string

Stéphane Oudard

http://www.w3.org/2001/XMLSchema#string

P304

115-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

19152

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA065044

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

356

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6585086

http://www.w3.org/2001/XMLSchema#string

P698

17215529

http://www.w3.org/2001/XMLSchema#string